Are you over 18 and want to see adult content?
More Annotations
A complete backup of yourultimatespeech.com
Are you over 18 and want to see adult content?
A complete backup of comfortdental.com
Are you over 18 and want to see adult content?
A complete backup of ashleyfurniture.com
Are you over 18 and want to see adult content?
A complete backup of hildenboroughstationtaxis.co.uk
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of https://www.hungama.com/movie/lights-out/22239365/
Are you over 18 and want to see adult content?
A complete backup of https://www.lolicit.org/tags.php?tag=straight+shota
Are you over 18 and want to see adult content?
A complete backup of https://chinaq.me/jp210123/
Are you over 18 and want to see adult content?
A complete backup of https://sabrinalynnvipfun.weebly.com/
Are you over 18 and want to see adult content?
Text
TEAM
This is the Age of Evidence. Where a new definition of diagnostic truth is changing patient care as we know it. Where physicians and patients can now benefit from the evolution of healthcare and know, by design, the answers they seek. Veracyte gives patients a clearer path for the future. We are leading in the Age of Evidence.OUR PRODUCTS
6000 Shoreline Court Suite 300 South San Francisco, CA 94080 Driving Directions. Phone: 650.243.6300 Fax: 650.243.6301OUR PRODUCTS
The Afirma XA provides physicians with genomic alteration information from the same FNA samples that are used in Afirma GSC testing. The test may enable physicians to confidently tailor surgery strategy or treatment options for patients whose thyroid nodules are cancerous or suspicious for cancer. The RNA sequencing-based test measures 905 DNA OVERVIEW | VERACYTE, INC. OVERVIEW. Veracyte is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company’s products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physiciansand patients a
VERACYTE, INC. ANNOUNCES CEO SUCCESSION PLAN Veracyte, Inc. Announces CEO Succession Plan. Bonnie Anderson, Cofounder and CEO, to Assume Active Role as Executive Chairman; Marc Stapley to Become Chief Executive Officer. SOUTH SAN FRANCISCO, Calif. -- (BUSINESS WIRE)--May 10, 2021-- Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, today announced its executiveOUR PRODUCTS
The Prosigna test is performed in laboratories around the world on the nCounter Dx Analysis System, which offers a reproducible and cost-effective way to analyze many genes simultaneously with high sensitivity and precision, while requiring minimum hands-on time in the laboratory. Learn more about the Prosigna Breast Cancer SignatureAssay.
VERACYTE TO ACQUIRE DECIPHER BIOSCIENCES Veracyte expects the acquisition of Decipher Biosciences to significantly accelerate its revenue growth in 2021 and to expand the near-term addressable market for Veracyte’s current and pipeline genomic tests from approximately $10 billion to an estimated $12 billion. Veracyte estimates that the acquisition will further expandits long-term
VERACYTE COMPLETES ACQUISITION OF DECIPHER BIOSCIENCES Tina Nova, Ph.D., named Veracyte’s general manager, urologic cancers. SOUTH SAN FRANCISCO, Calif. -- (BUSINESS WIRE)--Mar. 15, 2021-- Veracyte, Inc. (Nasdaq: VCYT) today announced it has completed its acquisition of Decipher Biosciences, Inc. to further solidify its global leadership in genomic diagnostics, with an expanded reach into7 of
PRESS RELEASES
PRESS RELEASES. SOUTH SAN FRANCISCO, Calif. -- (BUSINESS WIRE)--May 26, 2021-- Veracyte, Inc . (Nasdaq: VCYT), a global genomic diagnostics company, announced today that Bonnie H. Anderson , chairman, chief executive officer and incoming executive chairman, and Marc Stapley , incoming chief executive officer, are.SEC FILINGS
0001384101-21-000080.xls. EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA. May 10, 2021. 10-Q. Quarterly report which provides a continuing view of a company's financial position. View HTML. 0001384101-21-000082.pdf. VERACYTEWHO WE AREWHAT WE DOOUR PRODUCTSINVESTORSNEWS & EVENTSJOIN OURTEAM
This is the Age of Evidence. Where a new definition of diagnostic truth is changing patient care as we know it. Where physicians and patients can now benefit from the evolution of healthcare and know, by design, the answers they seek. Veracyte gives patients a clearer path for the future. We are leading in the Age of Evidence.OUR PRODUCTS
6000 Shoreline Court Suite 300 South San Francisco, CA 94080 Driving Directions. Phone: 650.243.6300 Fax: 650.243.6301OUR PRODUCTS
The Afirma XA provides physicians with genomic alteration information from the same FNA samples that are used in Afirma GSC testing. The test may enable physicians to confidently tailor surgery strategy or treatment options for patients whose thyroid nodules are cancerous or suspicious for cancer. The RNA sequencing-based test measures 905 DNA OVERVIEW | VERACYTE, INC. OVERVIEW. Veracyte is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company’s products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physiciansand patients a
VERACYTE, INC. ANNOUNCES CEO SUCCESSION PLAN Veracyte, Inc. Announces CEO Succession Plan. Bonnie Anderson, Cofounder and CEO, to Assume Active Role as Executive Chairman; Marc Stapley to Become Chief Executive Officer. SOUTH SAN FRANCISCO, Calif. -- (BUSINESS WIRE)--May 10, 2021-- Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, today announced its executiveOUR PRODUCTS
The Prosigna test is performed in laboratories around the world on the nCounter Dx Analysis System, which offers a reproducible and cost-effective way to analyze many genes simultaneously with high sensitivity and precision, while requiring minimum hands-on time in the laboratory. Learn more about the Prosigna Breast Cancer SignatureAssay.
VERACYTE TO ACQUIRE DECIPHER BIOSCIENCES Veracyte expects the acquisition of Decipher Biosciences to significantly accelerate its revenue growth in 2021 and to expand the near-term addressable market for Veracyte’s current and pipeline genomic tests from approximately $10 billion to an estimated $12 billion. Veracyte estimates that the acquisition will further expandits long-term
VERACYTE COMPLETES ACQUISITION OF DECIPHER BIOSCIENCES Tina Nova, Ph.D., named Veracyte’s general manager, urologic cancers. SOUTH SAN FRANCISCO, Calif. -- (BUSINESS WIRE)--Mar. 15, 2021-- Veracyte, Inc. (Nasdaq: VCYT) today announced it has completed its acquisition of Decipher Biosciences, Inc. to further solidify its global leadership in genomic diagnostics, with an expanded reach into7 of
PRESS RELEASES
PRESS RELEASES. SOUTH SAN FRANCISCO, Calif. -- (BUSINESS WIRE)--May 26, 2021-- Veracyte, Inc . (Nasdaq: VCYT), a global genomic diagnostics company, announced today that Bonnie H. Anderson , chairman, chief executive officer and incoming executive chairman, and Marc Stapley , incoming chief executive officer, are.SEC FILINGS
0001384101-21-000080.xls. EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA. May 10, 2021. 10-Q. Quarterly report which provides a continuing view of a company's financial position. View HTML. 0001384101-21-000082.pdf. WHO WE ARE - VERACYTE Veracyte is a pioneering genomic diagnostics company. Our tests provide trustworthy and actionable ANSWERS that improve care throughout the patient journey. We ask the right questions and provide answers that give physicians and patients a clearer path forward. Our tests leverage innovations in genomic technology and machine learningto enable
VERACYTE ANNOUNCES FIRST QUARTER 2021 FINANCIAL RESULTS SOUTH SAN FRANCISCO, Calif. -- (BUSINESS WIRE)--May 10, 2021-- Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the first quarter ended March 31, 2021, which were in line with its previously announced, preliminary first-quarter results. The company also provided an update on recent business progress. VERACYTE ANNOUNCES DE NOVO CLASSIFICATION REQUEST TO FDA SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jun. 9, 2020-- Veracyte, Inc. (Nasdaq: VCYT) today announced its submission of a De Novo classification request to the U.S. Food & Drug Administration (FDA) for the nCounter® Dx LymphMark™ Assay, a novel, genomic lymphoma subtyping test. The in vitro diagnostic test is used on the nCounter Flex Analysis System, Veracyte’s diagnosticsOUR PRODUCTS
The Prosigna test is performed in laboratories around the world on the nCounter Dx Analysis System, which offers a reproducible and cost-effective way to analyze many genes simultaneously with high sensitivity and precision, while requiring minimum hands-on time in the laboratory. Learn more about the Prosigna Breast Cancer SignatureAssay.
VERACYTE ANNOUNCES RETIREMENT OF CFO AND PRELIMINARY FIRST Keith Kennedy will retire following Q1 earnings release and 10-Q; Jane Alley appointed as acting CFO; Veracyte to conduct CFO search. SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Apr. 15, 2021-- Veracyte, Inc. (Nasdaq: VCYT) announced that Keith Kennedy, chief financial officer and chief operating officer, will retire from the company, effective May 15, 2021, following the company’s release VERACYTE ANNOUNCES EXPANSION OF COLLABORATION WITH THE Collaboration to Focus on 9,000-Patient Clinical Trial for Development of Future Lung Cancer Early-Detection Tests. SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Dec. 15, 2020-- Veracyte, Inc. (Nasdaq: VCYT) today announced it has expanded its long-term strategic collaboration with the Lung Cancer Initiative at Johnson & Johnson 1.The collaboration will include a focus on the NOBLE VERACYTE ANNOUNCES NEW PIVOTAL CLINICAL VALIDATION DATA AT Company to hold webcast to discuss findings on Thursday, May 20, at 10:00 a.m. ET. SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May 19, 2021-- Veracyte, Inc. (Nasdaq: VCYT) today announced pivotal clinical validation data showing that the company’s noninvasive nasal swab test can significantly improve the early assessment of lung cancer.PRESS RELEASES
PRESS RELEASES. SOUTH SAN FRANCISCO, Calif. -- (BUSINESS WIRE)--May 26, 2021-- Veracyte, Inc . (Nasdaq: VCYT), a global genomic diagnostics company, announced today that Bonnie H. Anderson , chairman, chief executive officer and incoming executive chairman, and Marc Stapley , incoming chief executive officer, are. BAYER AND VERACYTE ANNOUNCE PRECISION ONCOLOGY WHIPPANY, N.J. & SAN FRANCISCO--(BUSINESS WIRE)--Dec. 22, 2020-- Bayer and Veracyte (Nasdaq: VCYT) today announced a new collaboration to advance the Precision Oncology Patient Identification Program in thyroid cancer. Through the program, Bayer will offer testing with Veracyte’s Afirma Xpression Atlas (XA) to identify underlying genomic drivers, including NTRK gene fusions, VERACYTE TO UNVEIL PRACTICE-CHANGING GENOMIC DIAGNOSTICS About Veracyte. Veracyte (Nasdaq: VCYT) is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of genomic tests leverage advances in genomic science and technology, enabling patients to avoid risky, VERACYTEWHO WE AREWHAT WE DOOUR PRODUCTSINVESTORSNEWS & EVENTSJOIN OURTEAM
This is the Age of Evidence. Where a new definition of diagnostic truth is changing patient care as we know it. Where physicians and patients can now benefit from the evolution of healthcare and know, by design, the answers they seek. Veracyte gives patients a clearer path for the future. We are leading in the Age of Evidence. OVERVIEW | VERACYTE, INC.OVERVIEWPRESS RELEASESEVENTS & PRESENTATIONSCORPORATE GOVERNANCESEC FILINGS OVERVIEW. Veracyte is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company’s products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physiciansand patients a
OUR PRODUCTS
The Afirma XA provides physicians with genomic alteration information from the same FNA samples that are used in Afirma GSC testing. The test may enable physicians to confidently tailor surgery strategy or treatment options for patients whose thyroid nodules are cancerous or suspicious for cancer. The RNA sequencing-based test measures 905 DNA EVENTS & PRESENTATIONS Contact Information. Investor & Media Contact: Tracy Morris. tracy.morris@veracyte.com. 650.380.4413. Disclaimer. The information in our press releases and webcasts should be considered accurate only as of the date of the press release or presentation. We disclaim any obligation to supplement or update the information in these pressreleases or
VERACYTE ANNOUNCES NEW DATA REINFORCING FOUNDATIONAL SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct. 19, 2020-- Veracyte, Inc., (Nasdaq: VCYT) today announced that new data presented at the CHEST Annual Meeting 2020 show that a genomic smoking index developed for use on samples obtained from the main lung airway can also be detected in nasal samples.The findings, shared in an oral presentation at the virtual meeting, reinforceOUR PRODUCTS
The Envisia Genomic Classifier is the first commercially available genomic test to improve the diagnosis of idiopathic pulmonary fibrosis (IPF). The test harnesses the power of RNA sequencing and machine learning to improve physicians’ ability to differentiate IPF from other interstitial lung diseases (ILD) without the need for invasive VERACYTEWHO WE AREWHAT WE DOOUR PRODUCTSINVESTORSNEWS & EVENTSJOIN OURTEAM
This is the Age of Evidence. Where a new definition of diagnostic truth is changing patient care as we know it. Where physicians and patients can now benefit from the evolution of healthcare and know, by design, the answers they seek. Veracyte gives patients a clearer path for the future. We are leading in the Age of Evidence. OVERVIEW | VERACYTE, INC.OVERVIEWPRESS RELEASESEVENTS & PRESENTATIONSCORPORATE GOVERNANCESEC FILINGS OVERVIEW. Veracyte is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company’s products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physiciansand patients a
OUR PRODUCTS
The Afirma XA provides physicians with genomic alteration information from the same FNA samples that are used in Afirma GSC testing. The test may enable physicians to confidently tailor surgery strategy or treatment options for patients whose thyroid nodules are cancerous or suspicious for cancer. The RNA sequencing-based test measures 905 DNA EVENTS & PRESENTATIONS Contact Information. Investor & Media Contact: Tracy Morris. tracy.morris@veracyte.com. 650.380.4413. Disclaimer. The information in our press releases and webcasts should be considered accurate only as of the date of the press release or presentation. We disclaim any obligation to supplement or update the information in these pressreleases or
VERACYTE ANNOUNCES NEW DATA REINFORCING FOUNDATIONAL SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct. 19, 2020-- Veracyte, Inc., (Nasdaq: VCYT) today announced that new data presented at the CHEST Annual Meeting 2020 show that a genomic smoking index developed for use on samples obtained from the main lung airway can also be detected in nasal samples.The findings, shared in an oral presentation at the virtual meeting, reinforceOUR PRODUCTS
The Envisia Genomic Classifier is the first commercially available genomic test to improve the diagnosis of idiopathic pulmonary fibrosis (IPF). The test harnesses the power of RNA sequencing and machine learning to improve physicians’ ability to differentiate IPF from other interstitial lung diseases (ILD) without the need for invasive SET UP PRIOR TO BRONCHOSCOPY E. F. T 844.464.5864 (844.464.lung) T 650.243.6335 Retain this bag to ship 2 copies (white and pink) of the Percepta Requisition Form and Percepta Collection Tube. VERACYTE ANNOUNCES DE NOVO CLASSIFICATION REQUEST TO FDA SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jun. 9, 2020-- Veracyte, Inc. (Nasdaq: VCYT) today announced its submission of a De Novo classification request to the U.S. Food & Drug Administration (FDA) for the nCounter® Dx LymphMark™ Assay, a novel, genomic lymphoma subtyping test. The in vitro diagnostic test is used on the nCounter Flex Analysis System, Veracyte’s diagnosticsPRESS RELEASES
PRESS RELEASES. SOUTH SAN FRANCISCO, Calif. -- (BUSINESS WIRE)--May 26, 2021-- Veracyte, Inc . (Nasdaq: VCYT), a global genomic diagnostics company, announced today that Bonnie H. Anderson , chairman, chief executive officer and incoming executive chairman, and Marc Stapley , incoming chief executive officer, are. VERACYTE ANNOUNCES NEW DATA REINFORCING FOUNDATIONAL SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct. 19, 2020-- Veracyte, Inc., (Nasdaq: VCYT) today announced that new data presented at the CHEST Annual Meeting 2020 show that a genomic smoking index developed for use on samples obtained from the main lung airway can also be detected in nasal samples.The findings, shared in an oral presentation at the virtual meeting, reinforce VERACYTE ANNOUNCES NEXT-GENERATION PERCEPTA GENOMIC The Investor Relations website contains information about Veracyte, Inc.'s business for stockholders, potential investors, and financialanalysts.
SEC FILINGS
0001384101-21-000080.xls. EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA. May 10, 2021. 10-Q. Quarterly report which provides a continuing view of a company's financial position. View HTML. 0001384101-21-000082.pdf.OUR PRODUCTS
6000 Shoreline Court Suite 300 South San Francisco, CA 94080 Driving Directions. Phone: 650.243.6300 Fax: 650.243.6301 WHO WE ARE - VERACYTE 6000 Shoreline Court Suite 300 South San Francisco, CA 94080 Driving Directions. Phone: 650.243.6300 Fax: 650.243.6301 WHO WE ARE - VERACYTE Bonnie H. Anderson. Chairman of the Board and Chief Executive Officer. Her career spans over 30 years in regulated diagnostics and life science markets. Ms. Anderson cofounded Veracyte in 2008 and served as the company’s President and Chief Executive Officer until 2016, when she was also appointed Chairman of the Board.VERACYTE
Veracyte representatives are happy to assist you and to discuss how to integrate our tests into your practice. Veracyte to Acquire HalioDx, Solidifying Global Leadership in Cancer Diagnostics Learn More* WHO WE ARE
* ABOUT US
* AGE OF EVIDENCE
* LEADERSHIP
* Executive Team
* Board of Directors* Advisors
* CONTACT US
* WHAT WE DO
* OUR APPROACH
* OUR ONCOLOGY PORTFOLIO* OUR TECHNOLOGY
* OUR PRODUCTS
* OVERVIEW
* AFIRMA®
* PERCEPTA®
* ENVISIA®
* PROSIGNA®
* PIPELINE
* PUBLICATIONS & ABSTRACTS * SAFETY DATA SHEETS & LICENSES* INVESTORS
* OVERVIEW
* PRESS RELEASES
* EVENTS & PRESENTATIONS * CORPORATE GOVERNANCE * Executive Leadership * Board of Directors * Committee Composition* SEC FILINGS
* STOCK INFORMATION
* ANALYST COVERAGE
* INVESTOR FAQS
* INFORMATION REQUESTS* NEWS & EVENTS
* IN THE NEWS
* PRESS RELEASES
* EVENTS
* CORPORATE RECOGNITION* MEDIA RESOURCES
* SIGN UP FOR NEWS UPDATES* JOIN OUR TEAM
* OUR CULTURE
* JOB OPENINGS
* SEARCH
Veracyte to Acquire HalioDx, Solidifying Global Leadership in Cancer Diagnostics Learn More* WHO WE ARE
* ABOUT US
* AGE OF EVIDENCE
* LEADERSHIP
* Executive Team
* Board of Directors* Advisors
* CONTACT US
* WHAT WE DO
* OUR APPROACH
* OUR ONCOLOGY PORTFOLIO* OUR TECHNOLOGY
* OUR PRODUCTS
* OVERVIEW
* AFIRMA®
* PERCEPTA®
* ENVISIA®
* PROSIGNA®
* PIPELINE
* PUBLICATIONS & ABSTRACTS * SAFETY DATA SHEETS & LICENSES* INVESTORS
* OVERVIEW
* PRESS RELEASES
* EVENTS & PRESENTATIONS * CORPORATE GOVERNANCE * Executive Leadership * Board of Directors * Committee Composition* SEC FILINGS
* STOCK INFORMATION
* ANALYST COVERAGE
* INVESTOR FAQS
* INFORMATION REQUESTS* NEWS & EVENTS
* IN THE NEWS
* PRESS RELEASES
* EVENTS
* CORPORATE RECOGNITION* MEDIA RESOURCES
* SIGN UP FOR NEWS UPDATES* JOIN OUR TEAM
* OUR CULTURE
* JOB OPENINGS
Why Veracyte?
My father was a scientist and taught me to be curious about the world around me. That curiosity lead me to become a research scientist. The research I do is making a huge impact on patient's lives everyday telling them if they need surgery or not. That's why I'm here.Real People
Discovering
Real Answers.
JOSHUA BABIARZ
Principal Scientist
Veracyte
This is the Age of Evidence. Where a new definition of diagnostic truth is changing patient care as we know it. Where physicians and patients can now benefit from the evolution of healthcare and know, by design, the answers they seek. Veracyte gives patients a clearer path for the future. We are leading in the Age of Evidence.LEARN MORE >
our impact
LATEST NEWS
New data published in The Lancet Respiratory Medicine show that the Envisia Genomic Classifier improves diagnosis of IPF learn more >LATEST NEWS
Veracyte Launches Next-Generation Percepta® Genomic Sequencing Classifier for improved lung cancer diagnosis learn more >WATCH
Bonnie Anderson, Veracyte CEO interview with Bill Vick/PF Warriors about the Envisia Genomic Classifier and plans to transform IPF/ILDdiagnosis
WATCH NOW >
latest news
news and updates
------------------------- ASCO: New data set up Veracyte’s nasal swab lung cancer test for launch later this yearFierce Biotech
May 19, 2021
------------------------- Hormone Therapy for Prostate Cancer? A Genetic Test Could Help Decide Cancer Currents Blog, National Cancer InstituteMay 15, 2021
------------------------- Meet 22 women who launched and led startups to an IPO, an accomplishment few female founders have ever reachedBusiness Insider
Feb 9, 2021
-------------------------*
Who We Are
Who We Are
* About Us
* Age of Evidence
* Leadership
Executive Team
Board of Directors
Advisors
* Contact Us
*
What We Do
What We Do
* Our Approach
* Our Oncology Portfolio* Our Technology
*
Our Products
Our Products
* Overview
* Afirma®
* Percepta®
* Envisia®
* Prosigna®
* Pipeline
* Publications & Abstracts * Safety Data Sheets & Licenses*
Investors
Investors
* Overview
* Press Releases
* Events & Presentations * Corporate Governance Executive LeadershipBoard of Directors
Committee Composition* SEC Filings
* Stock Information
* Analyst Coverage
* Investor FAQs
* Information Requests*
News & Events
News & Events
* In The News
* Press Releases
* Events
* Corporate Recognition* Media Resources
* Sign Up For News Updates*
Join Our Team
Join Our Team
* Our Culture
* Job Openings
*
Veracyte Headquarters 6000 Shoreline CourtSuite 300
South San Francisco, CA 94080Driving Directions
Phone: 650.243.6300
Fax: 650.243.6301
Veracyte – Austin
12357-A Riata Trace Parkway Building 5, Suite 100Austin, TX 78727
Driving Directions
© 2021 Veracyte, Inc. All rights reserved.Contact Us
Privacy Policy  | Terms and Conditions| Terms of Sale
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0